Oh it will, the reason why funds haven't gotten in yet is because the contract hasn't been signed yet. Novartis has until October 2017 after the phase 2b trial starts to decide. I don't believe that Novartis will wait that long though once Conatus starts its phase 2b LC trial in a few months time.
Correction: Bret Jensen has sold calls, not directly shorted. I don't know if the contract writers Short shares, or Buy shares as a hedge.
We won't know until all the institutional investors report, to see that the holders got out on the Novartis announcement or continue to hold.
Congrats for holding through the unknown.
I haven't traded Bio stocks really too much until the last couple of months. So I an learning as I go. Have already made 4 mistakes. Most of which is not selling on blips and buying back lower.